Arvinas, Inc.

NASDAQ:ARVN

7.2 (USD) • At close May 30, 2025
Bedrijfsnaam Arvinas, Inc.
Symbool ARVN
Munteenheid USD
Prijs 7.2
Beurswaarde 525,538,080
Dividendpercentage 0%
52-weken bereik 5.9 - 34.11
Industrie Biotechnology
Sector Healthcare
CEO Dr. John G. Houston Ph.D.
Website https://www.arvinas.com

An error occurred while fetching data.

Over Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men

Vergelijkbare Aandelen

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

0.426 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

77.56 USD

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

48.52 USD

Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

BEAM

15.83 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

2.02 USD

Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

1.21 USD

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

1.32 USD

Amicus Therapeutics, Inc. logo

Amicus Therapeutics, Inc.

FOLD

6.07 USD

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

IOVA

1.75 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)